Pharmaceutical Investing

U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® as First and Only Treatment for People with Acute Hepatitis C Virus

Pharmaceutical Investing

Pharma Outlook

Pharmaceutical Investing

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

Pharmaceutical Investing

Traws Pharma

Pharmaceutical Investing

Bird Flu Vaccine Stocks: 8 Companies Developing H5N1 Vaccines

Life Science Investing News

AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award Contest to Support Their Professional Goals

Pharmaceutical Investing

AbbVie to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Pharmaceutical Investing

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

Pharmaceutical Investing

Pfizer's BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

Pharmaceutical Investing

AbbVie Partners with Chicago Cubs on "Striking Out Cancer"

Pharmaceutical Investing

Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders

Geography

Encouraging SRC Findings on Ph I/II Skin Cancer Trial

Pharmaceutical Investing

Latest pharmaceutical News

More pharmaceutical News

Outlook Reports

Resource
Tech
Life Science

Browse Companies

Resource
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES
×